How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

7,648 results for

aspirin and gastrointestinal bleeding

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. the Efficiency of Thalidomide for Recurrent Small Intestinal Bleeding Due to Gastrointestinal Vascular Malformation

by Zhizheng Ge, Shanghai Jiao Tong University School of Medicine: Gastrointestinal vascular malformation thalidomide Small intestinal bleeding Additional relevant MeSH terms: Layout table for MeSH terms Hemorrhage Congenital Abnormalities Vascular Malformations Gastrointestinal Hemorrhage Pathologic Processes Cardiovascular Abnormalities Cardiovascular Diseases Gastrointestinal Diseases Digestive System Diseases Thalidomide Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs (...) the Efficiency of Thalidomide for Recurrent Small Intestinal Bleeding Due to Gastrointestinal Vascular Malformation the Efficiency of Thalidomide for Recurrent Small Intestinal Bleeding Due to Gastrointestinal Vascular Malformation - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number

2015 Clinical Trials

62. Salazopyrine (A07EC01 (intestinal anti-inflammatory agents)) - Ulcerative colitis, Crohn's disease in the colon, Rheumatoid arthritis

sulfonamides, are nausea and vomiting. Patients with impaired renal function are exposed to an increased risk of severe toxicity. Treatment is symptomatic and must be adapted, including alkalinisation of urine. Development of methaemoglobinaemia or sulfhaemoglobinaemia must be monitored in patients. If this occurs, treat appropriately. 5.1. Pharmacodynamic properties INTESTINAL ANTIINFLAMMATORY AGENTS (A: alimentary tract and metabolism) 5-aminosalicylic acid or 5-ASA is the fraction of sulfasalazine (...) cholangitis or history of colon cancer in a first-degree relative. A meta-analysis of nine observation studies (three cohort studies and six case-control studies) having included 334 cases of colorectal cancer and 140 cases of dysplasia for a total of 1932 patients with UC, revealed that the risk of colorectal cancer was around 50% lower in patients regularly taking HAS - Medical, Economic and Public Health Assessment Division 15/15 5-aminosalicylic acid (5-ASA) than in those taking 5-ASA irregularly

2015 Haute Autorite de sante

63. Effect of pharmacological therapies for stroke prevention on major gastrointestinal bleeding in patients with atrial fibrillation Full Text available with Trip Pro

-conducted review found that adjusted-dose vitamin K antagonists increased the risk of major gastrointestinal bleeding compared with placebo or aspirin when used for stroke prevention in atrial fibrillation patients; combining vitamin K antagonists with aspirin also increased this risk. The authors' findings are generally reliable but limited by the small number of trials and rarity of events. Authors' objectives To investigate the incidence of major gastrointestinal bleeding when using various (...) were eligible for inclusion. Eligible trials had to report the incidence of major gastrointestinal bleeding. Trials of patients with postoperative atrial fibrillation or valvular disease were excluded. The included trials evaluated the following agents: aspirin, clopidogrel, dabigatran, triflusal, vitamin K antagonists (adjusted-dose or low-intensity), warfarin (adjusted-dose or low-intensity) and ximelagatran. There were five placebo or control arms, nine aspirin (or triflusal or indoprofen) arms

2012 DARE.

64. Mortality rate and risk factors for gastrointestinal bleeding in elderly patients. (Abstract)

± 7.6 years, F:M 0.8:1), lower GIB in 51 patients (mean age 79.4 ± 7.1 years, F:M 0.9:1), and both upper/lower GIB in 3 patients. Hemorrhagic gastritis/duodenitis and colonic diverticular disease were the most common causes. The LOS of patients with GIB was 11.7 ± 8.1 days, with a 3.3% in-hospital and a 9.4% 3-month mortality rates. Liver cirrhosis (OR 5.64; CI 2.51-12.65), non-ASA antiplatelet agents (OR 2.70; CI 1.23-5.90), and CIRS index of comorbidity >3 (OR 2.41; CI 1.16-4.98) were associated (...) Mortality rate and risk factors for gastrointestinal bleeding in elderly patients. Gastrointestinal bleeding (GIB) is burdened by high mortality rate that increases with aging. Elderly patients may be exposed to multiple risk factors for GIB. We aimed at defining the impact of GIB in elderly patients.Since 2008, samples of elderly patients (age ≥ 65 years) with multimorbidity admitted to 101 internal medicine wards across Italy have been prospectively enrolled and followed-up (REPOSI registry

2018 European journal of internal medicine

65. Peptic Ulcer Is the Most Common Cause of Non-Variceal Upper-Gastrointestinal Bleeding (NVUGIB) in China Full Text available with Trip Pro

Peptic Ulcer Is the Most Common Cause of Non-Variceal Upper-Gastrointestinal Bleeding (NVUGIB) in China BACKGROUND This study aimed to discover the common cause of non-variceal upper-gastrointestinal bleeding (NVUGIB) by conducting a multi-center retrospective study from 2008 to 2012. MATERIAL AND METHODS Hospitalized patients ages ≥18 years old, from 8 hospitals in China, diagnosed with NVUGIB by endoscopy from 1 January 2008 to 31 December 2012 were enrolled. Questionnaires were developed (...) of 14.41% (429/2977) of patients had co-morbid conditions, 92.85% (2764/2977) used proton-pump inhibitors (PPIs) prior to endoscopic treatment, 19.65% (585/2977) underwent emergency endoscopy, and 23.45% (698/2977) received a transfusion of red blood cell suspensions. A total of 5.34% (159/2977) underwent endoscopic therapy, with a treatment rate of 16.9% in high-risk peptic ulcer patients (96/568). A total of 7.69% (237/2977) were administered aspirin, of whom 32.50% (77/237) resumed aspirin intake

2018 Medical science monitor : international medical journal of experimental and clinical research

66. Impact of INR monitoring, reversal agent use, heparin bridging, and anticoagulant interruption on rebleeding and thromboembolism in acute gastrointestinal bleeding. Full Text available with Trip Pro

Impact of INR monitoring, reversal agent use, heparin bridging, and anticoagulant interruption on rebleeding and thromboembolism in acute gastrointestinal bleeding. Anticoagulant management of acute gastrointestinal bleeding (GIB) during the pre-endoscopic period has not been fully addressed in American, European, or Asian guidelines. This study sought to evaluate the risks of rebleeding and thromboembolism in anticoagulated patients with acute GIB.Baseline, endoscopy, and outcome data were (...) , low platelet count and albumin level, and low-dose aspirin use but not HAS-BLED score, any endoscopic results, heparin bridge, or international normalized ratio (INR) ≥ 2.5. Risks for thromboembolism were INR ≥ 2.5, difference in onset and pre-endoscopic INR, reversal agent use, and anticoagulant interruption but not CHA2DS2-VASc score, any endoscopic results, or heparin bridge. In patients without reversal agent use, heparin bridge, or anticoagulant interruption, there was only one rebleeding

2017 PLoS ONE

67. Gastrointestinal Bleeding With Edoxaban Versus Warfarin: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction). Full Text available with Trip Pro

with atrial fibrillation. The risk factors and clinical impact of gastrointestinal bleeding (GIB) in this trial have not been described in detail.This analysis was undertaken to identify risk factors for major GIB (MGIB) and compare the severity and outcomes of GIB with edoxaban and warfarin. During 2.8 years mean follow-up, there were 579 MGIB (1.22% per year), of which 63 were life-threatening or fatal (0.13% per year). Male sex, increased age, prior GIB, concomitant aspirin, lower baseline hemoglobin (...) Gastrointestinal Bleeding With Edoxaban Versus Warfarin: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction). The ENGAGE AF-TIMI 48 trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction) compared higher-dose edoxaban regimen (HD-ER) and lower-dose edoxaban regimen with well-managed warfarin in 21 105 patients

2018 Circulation. Cardiovascular quality and outcomes

68. NOACs/DOACs: Management of Bleeding

of 6 Severe/Life-threatening bleeding e.g. intracranial hemorrhage, severe GI bleed Initial management ? Hold anticoagulant therapy ? Initiate resuscitation in a monitored setting ? Assess the patient to determine the cause of bleeding ? Apply local hemostatic measures (e.g. compression, packing, splinting) if applicable ? Consult an expert urgently (hematologist, internist, ER physician, pharmacist) for advice ? Refer for procedural/surgical intervention if appropriate ? Obtain CBC, PT/INR, PTT (...) to anatomical cause PCC (Octaplex®) rivaroxaban apixaban edoxaban dabigatran* ? 50 units/kg, max 3000 units ? Mix diluent and PCC following manufacturer instructions ? infuse at 1 mL/min followed by maximum 3 mL/min (180 mL/hr) per institution/Blood Bank instructions ? Contraindicated in heparin-induced thrombocytopenia ? For life-threatening bleeding (e.g. intracranial hemorrhage) give 2000 units IV STAT if weight not available and cannot delay reversal PCC (Beriplex®) rivaroxaban apixaban edoxaban

2017 Thrombosis Interest Group of Canada

69. Over-the-counter analgesic powder use in patients presenting with intracerebral hemorrhage: A case series. Full Text available with Trip Pro

Over-the-counter analgesic powder use in patients presenting with intracerebral hemorrhage: A case series. Over-the-counter (OTC) analgesics including aspirin-containing powder formulations (BC Powder, Goody's Powder) (ACPFs) are commonly utilized in the United States. While the ACPFs have been associated with upper gastrointestinal bleeding, we describe a case series of patients presenting with intracerebral hemorrhage (ICH) within 24 hours of ingestion.We reviewed all ICH patients presenting (...) . All patients were African American and all except 1 patient were females. Three patients had no identified traditional stroke risk factors and 3 other patients had evidence of mild hypertension history.Over-the-counter analgesic powders containing high doses of aspirin including BC Powder and Goody's Powder may contribute to ICH in patients with no or minimal risk factors. Providers should inquire about the use of these powders in ICH patients particularly among African Americans.

2018 Medicine

70. Do NSAIDs and ASA Cause More Upper Gastrointestinal Bleeding in Elderly than Adults? Full Text available with Trip Pro

Do NSAIDs and ASA Cause More Upper Gastrointestinal Bleeding in Elderly than Adults? Purpose. NSAIDs and ASA may cause upper gastrointestinal bleeding (UGIB) both in adults and in elderly. There is no study that compares this increased bleeding risk between adult and elderly subjects. Methods. A total of 524 patients with UGIB were included in this study. The data of patients were, respectively, analyzed. Results. NSAIDs and ASA-associated UGIB rates were similar between <65 years (345 patients (...) ) (group 1) and ≥65 years (179 patients) (group 2) (28.4% versus 23.5%, p = 0.225 and 13% versus 19%, p = 0.071, resp.). Warfarin-associated UGIB was found significantly higher in group 2 than group 1. Elderly patients with NSAID-associated UGIB had significantly higher length of stay (LoS) and CoH than adult patients with NSAID-associated UGIB (p = 0.002 and 0.001, resp.). Elderly patients with ASA-associated UGIB had significantly higher CoH than adult patients with NSAID-associated UGIB. Conclusions

2016 Gastroenterology research and practice

71. Application of linked color imaging for detecting a previously bleeding colonic diverticulum Full Text available with Trip Pro

Application of linked color imaging for detecting a previously bleeding colonic diverticulum 30276355 2018 11 14 2468-4481 3 10 2018 Oct VideoGIE : an official video journal of the American Society for Gastrointestinal Endoscopy VideoGIE Application of linked color imaging for detecting a previously bleeding colonic diverticulum. 319-321 10.1016/j.vgie.2018.07.007 Tamari Hirosato H Department of Gastroenterology, Hiroshima City Asa Citizens Hospital, Hiroshima, Japan. Aoyama Taiki T Department (...) of Gastroenterology, Hiroshima City Asa Citizens Hospital, Hiroshima, Japan. Fukumoto Akira A Department of Gastroenterology, Hiroshima City Asa Citizens Hospital, Hiroshima, Japan. Mukai Shinichi S Department of Gastroenterology, Hiroshima City Asa Citizens Hospital, Hiroshima, Japan. Nagata Shinji S Department of Gastroenterology, Hiroshima City Asa Citizens Hospital, Hiroshima, Japan. eng Journal Article 2018 08 03 United States VideoGIE 101719677 2468-4481 BLI, blue laser imaging LCI, linked color imaging NBS

2018 VideoGIE

72. Gastrointestinal blood loss caused by controlled-release and conventional acetylsalicylic acid tablets. (Abstract)

Gastrointestinal blood loss caused by controlled-release and conventional acetylsalicylic acid tablets. Gastrointestinal blood loss has been studied following oral administration of the novel controlled-release acetylsalicylic acid tablet preparation Acetard and the instant-release acetylsalicylic acid tablet Magnecyl (Ph. Nord. 63). Acetard contains micro-encapsulated acetylsalicylic acid crystals having an in vitro release time of approximately 4 hours. The investigation was carried out (...) significantly less gastrointestinal blood loss as compared with the plain formulation, irrespective of whether Acetard was given twice or four times a day.

1979 Scandinavian journal of rheumatology Controlled trial quality: uncertain

73. Evaluation of Pazopanib on Bleeding in Subjects With Hereditary Haemorrhagic Telangiectasia

syndrome, major resection of the stomach or small bowel that could affect the absorption of study drug (eg, short bowel syndrome), active peptic ulcer, known intraluminal metastatic lesions/s with suspected bleeding, inflammatory bowel disease, ulcerative colitis or other gastrointestinal conditions with increased risk of perforation, lifetime history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess Subject has a history of cerebrovascular accident (including transient (...) telangiectasias at characteristic sites: lips, oral cavity, fingers, nose; c) visceral lesions: gastrointestinal (GI) telangiectasia, pulmonary, hepatic, cerebral or spinal arteriovenous malformations (AVMs); d) a first degree relative with HHT according to these criteria. Subject meets at least one of the following criteria: a) Severe epistaxis over previous 4 weeks defined as an average of at least 3 nose bleeds per week AND a total duration of greater than 15 min per week AND requiring iron therapy (oral

2014 Clinical Trials

74. Prospective analysis of delayed colorectal post-polypectomy bleeding. (Abstract)

Prospective analysis of delayed colorectal post-polypectomy bleeding. Although post-polypectomy bleeding is the most frequent complication after colonoscopic polypectomy, only few studies have investigated the incidence of bleeding prospectively. The aim of this study was to investigate the incidence of delayed post-polypectomy bleeding and its associated risk factors prospectively.Patients who underwent colonoscopic polypectomy at Kangbuk Samsung Hospital from January 2013 to December 2014 (...) were prospectively enrolled in this study. Trained nurses contacted patients via telephone 7 and 30 days after polypectomy and completed a standardized questionnaire regarding the development of bleeding. Delayed post-polypectomy bleeding was categorized as minor or major and early or late bleeding. Major delayed bleeding was defined as a > 2-g/dL drop in the hemoglobin level, requiring hospitalization for control of bleeding or blood transfusion; late delayed bleeding was defined as bleeding

2018 Surgical endoscopy

75. Factors associated with delayed bleeding after resection of large nonpedunculated colorectal polyps. (Abstract)

Factors associated with delayed bleeding after resection of large nonpedunculated colorectal polyps. Delayed bleeding is the most common significant complication after piecemeal endoscopic mucosal resection (p-EMR) of large nonpedunculated colorectal polyps (NPCPs). Risk factors for delayed bleeding are incompletely defined. We aimed to determine risk factors for delayed bleeding following p-EMR.Data were analyzed from a prospective tertiary center audit of patients with NPCPs ≥ 20 mm who (...) underwent p-EMR between 2010 and 2012. Patient, polyp, and procedure-related data were collected. Four post p-EMR defect factors were evaluated for interobserver agreement and included in analysis. Delayed bleeding severity was reported in accordance with guidelines. Predictors of bleeding were identified.Delayed bleeding requiring hospitalization occurred after 22 of 330 procedures (6.7 %). A total of 11 patients required blood transfusion; of these, 4 underwent urgent colonoscopy, 1 underwent

2018 Endoscopy

76. A risk-scoring model for the prediction of delayed bleeding after colorectal endoscopic submucosal dissection. (Abstract)

; 95% confidence interval [CI], 1.96-21.42; P = .002), large tumor (≥30 mm) (OR, 2.10; 95% CI, 1.01-4.40; P = .048), and use of antiplatelet agents except for aspirin alone (OR, 4.04; 95% CI, 1.44-11.30; P = .008). These 3 factors were incorporated into a risk-scoring model for prediction of delayed bleeding. As the score based on this system increased, the incidence of delayed bleeding increased in the validation cohort.The risk-scoring model incorporating tumor location, tumor size, and use (...) of antiplatelet agents can quantitatively predict the risk of delayed bleeding after colorectal ESD.Copyright © 2018 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved.

2018 Gastrointestinal endoscopy

77. Does Preendoscopy Rockall Score Safely Identify Low Risk Patients following Upper Gastrointestinal Haemorrhage? Full Text available with Trip Pro

Does Preendoscopy Rockall Score Safely Identify Low Risk Patients following Upper Gastrointestinal Haemorrhage? Objective. To determine if preendoscopy Rockall score (PERS) enables safe outpatient management of New Zealanders with upper gastrointestinal haemorrhage (UGIH). Methods. Retrospective analysis of adults with UGIH over 59 consecutive months. PERS, diagnosis, demographics, need for endoscopic therapy, transfusion or surgery and 30-day mortality and 14-day rebleeding rate (...) , and sensitivity and specificity of PERS for enabling safe discharge preendoscopy were calculated. Results. 424 admissions with UGIH. Median age was 74.3 years (range 19-93 years), with 55.1% being males. 30-day mortality was 4.6% and 14-day rebleeding rate was 6.0%. Intervention was required in 181 (46.6%): blood transfusion (147 : 37.9%), endoscopic intervention (75 : 19.3%), and surgery (8 : 2.1%). 42 (10.8%) had PERS = 0 with intervention required in 15 (35.7%). Females more frequently required

2015 Gastroenterology research and practice

78. DuoPlavin - clopidogrel / acetylsalicylic acid

, acidic, basic and oxidative conditions. Results indicate that the active substance obtained from Synthesis Routes 1 and 2 is stable when stored according to proposed conditions and confirmed the re-test period. Acetylsalicylic acid (ASA) Acetylsalicylic acid is chemically designated as Benzoic acid, 2-(acetyloxy) (CAS) or 2-(acetyloxy)- benzoic acid (IUPAC). It is also commonly known as Aspirin and has the following structure: O OH O O It is white crystalline powder with melting point at 156 - 161 °C (...) studies are listed in the table 1 below. Table 1 Study BDR4659: Bioequivalence between a tablet containing 75 mg of SR25990C and 75 mg of acetylsalicylic acid and the simultaneous administration of the separate formulations of the two drugs, to young healthy subjects. Open, crossover, randomized and single centre. Table 2 Page 18 of 37 Results are shown below in table 3 and figure 1: Table 3 Mean (CV%) pharmacokinetic parameters of SR26334, salicylic acid, and ASA, treatment ratio estimates and 90

2010 European Medicines Agency - EPARs

79. DuoCover - clopidogrel / acetylsalicylic acid

and oxidative conditions. Results indicate that the active substance obtained from Synthesis Routes 1 and 2 is stable when stored according to proposed conditions and confirmed the re-test period. Acetylsalicylic acid (ASA) Acetylsalicylic acid is chemically designated as Benzoic acid, 2-(acetyloxy) (CAS) or 2-(acetyloxy)- benzoic acid (IUPAC). It is also commonly known as Aspirin and has the following structure: O OH O O It is white crystalline powder with melting point at 156 - 161 °C, freely soluble (...) a tablet containing 75 mg of SR25990C and 75 mg of acetylsalicylic acid and the simultaneous administration of the separate formulations of the two drugs, to young healthy subjects. Open, crossover, randomized and single centre. Table 2 Page 18 of 37 Results are shown below in table 3 and figure 1: Table 3 Mean (CV%) pharmacokinetic parameters of SR26334, salicylic acid, and ASA, treatment ratio estimates and 90% CI’s for clopidogrel/ASA 75/75 mg tablets versus 75 mg clopidogrel tablets and 75 mg ASA

2010 European Medicines Agency - EPARs

80. Pharmacodynamic Equivalence of Ramipril 10 mg and Atorvastatin 40 mg Administered as a Cardiovascular (CV) Polypill Acetylsalicylic Acid-Atorvastatin-Ramipril (AAR) as Compared to Monotherapy

Pharmacodynamic Equivalence of Ramipril 10 mg and Atorvastatin 40 mg Administered as a Cardiovascular (CV) Polypill Acetylsalicylic Acid-Atorvastatin-Ramipril (AAR) as Compared to Monotherapy Pharmacodynamic Equivalence of Ramipril 10 mg and Atorvastatin 40 mg Administered as a Cardiovascular (CV) Polypill Acetylsalicylic Acid-Atorvastatin-Ramipril (AAR) as Compared to Monotherapy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting (...) registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Pharmacodynamic Equivalence of Ramipril 10 mg and Atorvastatin 40 mg Administered as a Cardiovascular (CV) Polypill Acetylsalicylic Acid-Atorvastatin-Ramipril (AAR) as Compared to Monotherapy The safety and scientific validity of this study is the responsibility of the study

2016 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>